NICE Rejects Janssen’s Treatment-Resistant Depression Drug Spravato
Company Criticizes Appraisal Processes
Draft guidance questions lack of evidence comparing new nasal treatment with older therapies.
You may also be interested in...
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.